Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
16 hedge funds and large institutions have $26.6M invested in Sigilon Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 9 reducing their positions, and 19 closing their positions.
61% more capital invested
Capital invested by funds: $16.5M → $26.6M (+$10.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.29% less ownership
Funds ownership: 54.55% → 47.27% (-7.3%)
50% less funds holding
Funds holding: 32 → 16 (-16)
84% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 19
89% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$288K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
+$96.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.53K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$951 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Cercano Management
Bellevue,
Washington
|
-$823K |
| 2 |
BlackRock
New York
|
-$584K |
| 3 |
Millennium Management
New York
|
-$259K |
| 4 |
Morgan Stanley
New York
|
-$91.2K |
| 5 |
Renaissance Technologies
New York
|
-$90K |
SGTX Hedge Fund Activity: Q2 2023 in Review
16 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q2 2023, worth a combined $26.6M — up 61% from $16.5M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SGTX and 3 opened new positions — a net loss of 16 holders — while 9 trimmed existing stakes and 1 added.
The largest buyer was Yakira Capital Management, opening a new position worth an estimated $288K. The largest seller was Cercano Management, exiting entirely with an estimated $823K sold.
- 16 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q2 2023, down from 32 in Q1 2023.
- Funds reported $26.6M of Sigilon Therapeutics, Inc. Common Stock stock for Q2 2023, up 61% quarter-over-quarter.
- 3 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q2 2023 and 19 closed out, a net change of -16 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q2 2023 was Yakira Capital Management, an estimated $288K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q2 2023 was Cercano Management, an estimated $823K sold.
Based on aggregated 13F filings for Q2 2023.